DiaMedica Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$37.5MTTM through 30 Jun 2026
Free Cash Flow -$31.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-74.3%ROE
-66.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio9.11x
Net Debt-$94.9Mnet cash position
Cash & Equivalents$5.1M
Quality Metrics
Altman Z-Score29.91
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2018: $500K
Diluted EPSFY2025: $-0.70
Dividend
No dividend
Capital Allocation
R&D Spend$29.3M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Clinical-Stage Drug Development | $0 | View detailsR&D expenses are expected to moderately increase as clinical trials progress globally. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.